Advanced search
Publication Cover
Bioscience, Biotechnology, and Biochemistry Volume 72, 2008 - Issue 9
Journal homepage
184
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

The Kringle Domain of Tissue-Type Plasminogen Activator Inhibits Extracellular Matrix-Induced Adhesion and Migration of Endothelial Cells

Byung Hun LEECancer Research Institute and Department of Biomedical Science, College of Medicine, The Catholic University of Korea
,
Hyun-Kyung KIMCancer Research Institute and Department of Biomedical Science, College of Medicine, The Catholic University of Korea
&
Young Ae JOECancer Research Institute and Department of Biomedical Science, College of Medicine, The Catholic University of Korea
Pages 2303-2308 | Received 12 Mar 2008, Accepted 17 May 2008, Published online: 22 May 2014

  • 1) Collen, D., On the regulation and control of fibrinolysis. Thromb. Haemost., 43, 77–89 (1980).
  • 2) Castellino, F. J., and Beals, J. M., The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XII. J. Mol. Evol., 26, 358–369 (1987).
  • 3) Kim, H. K., Lee, S. Y., Oh, H. K., Kang, B. H., Ku, H. J., Lee, Y., Shin, J. Y., Hong, Y. K., and Joe, Y. A., Inhibition of endothelial cell proliferation by the recombinant kringle domain of tissue-type plasminogen activator. Biochem. Biophys. Res. Commun., 304, 740–746 (2003).
  • 4) Shim, B. S., Kang, B. H., Hong, Y. K., Kim, H. K., Lee, I. H., Lee, S. Y., Lee, Y. J., Lee, S. K., and Joe, Y. A., The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem. Biophys. Res. Commun., 327, 1155–1162 (2005).
  • 5) Kang, B. H., Sim, B. S., Lee, S. Y., Lee, S. K., Hong, Y. K., and Joe, Y. A., Potent anti-tumor and prolonged survival effects of E. coli-derived non-glycosylated kringle domain of tissue-type plasminogen activator. Int. J. Oncol., 28, 361–367 (2006).
  • 6) Oh, H. K., Ha, J. M., O, E., Lee, B. H., Lee, S. K., Shim, B. S., Hong, Y. K., and Joe, Y. A., Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res., 67, 4851–4859 (2007).
  • 7) O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315–328 (1994).
  • 8) Cao, Y., Chen, A., An, S. S., Ji, R. W., Davidson, D., and Llinas, M., Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem., 272, 22924–22928 (1997).
  • 9) Kim, T. H., Kim, E., Yoon, D., Kim, J., Rhim, T. Y., and Kim, S. S., Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases. Angiogenesis, 5, 191–201 (2002).
  • 10) Kuba, K., Matsumoto, K., Date, K., Shimura, H., Tanaka, M., and Nakamura, T., HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res., 60, 6737–6743 (2000).
  • 11) Xin, L., Xu, R., Zhang, Q., Li, T. P., and Gan, R. B., Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem. Biophys. Res. Commun., 277, 186–190 (2000).
  • 12) Kim, J. S., Chang, J. H., Yu, H. K., Ahn, J. H., Yum, J. S., Lee, S. K., Jung, K. H., Park, D. H., Yoon, Y., Byun, S. M., and Chung, S. I., Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J. Biol. Chem., 278, 29000–29008 (2003).
  • 13) Kim, K. S., Hong, Y. K., Joe, Y. A., Lee, Y., Shin, J. Y., Park, H. E., Lee, I. H., Lee, S. Y., Kang, D. K., Chang, S. I., and Chung, S. I., Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells. J. Biol. Chem., 278, 11449–11456 (2003).
  • 14) Joe, Y. A., Kim, M. R., Shim, B. S., Oh, D. S., Hong, S. H., and Hong, Y. K., Antiangiogenic and antitumor activities of the cryptic fragments with kringle architecture. J. Appl. Pharmacol., 11, 205–213 (2003).
  • 15) Soff, G. A., Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev., 19, 97–107 (2000).
  • 16) Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., Everitt, L., Hubchak, S., Schnaper, H. W., and Pizzo, S. V., Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA, 96, 2811–2816 (1999).
  • 17) Tarui, T., Miles, L., and Takada, Y., Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem., 276, 39562–39568 (2001).
  • 18) Troyanovsky, B., Levchenko, T., Mansson, G., Matvijenko, O., and Holmgren, L., Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol., 152, 1247–1254 (2001).
  • 19) Davidson, D. J., Haskell, C., Majest, S., Kherzai, A., Egan, D. A., Walter, K. A., Schneider, A., Gubbins, E. F., Solomon, L., Chen, Z., Lesniewski, R., and Henkin, J., Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res., 65, 4663–4672 (2005).
  • 20) Stupack, D. G., and Cheresh, D., Integrins and angiogenesis. Curr. Top. Dev. Biol., 64, 207–238 (2004).
  • 21) Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R., Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest., 52, 2745–2756 (1973).
  • 22) Kim, H. K., Oh, D. S., Lee, S. B., Ha, J. M., and Joe, Y. A., Anti-migratory effect of TK1-2 is mediated in part by interfering with integrin α2β1. Mol. Cancer Ther., 7, 2133–2141 (2008).
  • 23) Ruegg, C., Dormond, O., and Mariotti, A., Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim. Biophys. Acta, 1654, 51–67 (2004).
  • 24) Davis, G. E., Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun., 182, 1025–1031 (1992).
  • 25) Staatz, W. D., Fok, K. F., Zutter, M. M., Adams, S. P., Rodriguez, B. A., and Santoro, S. A., Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J. Biol. Chem., 266, 7363–7367 (1991).
  • 26) Yamamoto, M., Yamato, M., Aoyagi, M., and Yamamoto, K., Identification of integrins involved in cell adhesion to native and denatured type I collagens and the phenotypic transition of rabbit arterial smooth muscle cells. Exp. Cell Res., 219, 249–256 (1995).
  • 27) Sudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M., and Kalluri, R., Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA, 100, 4766–4771 (2003).
  • 28) Wickstrom, S. A., Alitalo, K., and Keski-Oja, J., Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res., 62, 5580–5589 (2002).
  • 29) Bix, G., Fu, J., Gonzalez, E. M., Macro, L., Barker, A., Campbell, S., Zutter, M. M., Santoro, S. A., Kim, J. K., Hook, M., Reed, C. C., and Iozzo, R. V., Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell Biol., 166, 97–109 (2004).
  • 30) Ito, H., Rovira, II, Bloom, M. L., Takeda, K., Ferrans, V. J., Quyyumi, A. A., and Finkel, T., Endothelial progenitor cells as putative targets for angiostatin. Cancer Res., 59, 5875–5877 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.